Novo Nordisk A/S Common Stock (NVO)

Investors will want to see these key developments concerning Novo Nordisk's pipeline of new treatments.

The mid-cap biotech could become a notable player in the industry's hottest therapeutic area.

Pricing updates for major therapies from Novo Nordisk, Teva, AbbVie, and others eased sector worries.

JPMorgan said the implied net impact aligns with recent commentary from Novo Nordisk, Teva and AbbVie during earnings season.

Patients could soon access higher-dose injections.

Novo Nordisk stock jumped Wednesday on a lighter-than-feared discount for Ozempic and Wegovy under the IRA.

The weight loss drug market may approach almost $100 billion by the end of the decade.

Users pointed to emerging drug pipelines, GLP-1 expansion and rising M&A pressure across the sector.

Good news from a GLP-1 receptor agonist clinical trial hit the market today.

Discover Novo Nordisk (NVO), a potentially undervalued stock with strong profitability, solid financial health, and a good dividend yield.

Semaglutide was no better than a placebo.

Stocks were up sharply to start the holiday week.

Let's have a look at what is happening on the US markets before the opening bell on Monday. Below you can find the top gainers and losers in today's pre-market session.

The company said that it is discontinuing the trials.

The obesity drug producer has taken some hits throughout the past year, but it is beginning to punch back.

Many other drugmakers are attempting to break this duopoly, but this may not happen anytime soon.

November is a great month to be thankful for opportunities to invest in these fantastic companies.

Millions of people in the world are overweight, and Novo Nordisk hopes to capture a growing share of this lucrative treatment opportunity.

The management team conducted a cost-cutting effort that is likely to result in a more efficient business.

Vanda's tradipitant cut Wegovy-related vomiting by 50% in a new trial, prompting bullish analyst views and price targets.

KeyCorp, through its KeyBanc capital markets division, has issued a significantly more pessimistic forecast for LifeMD (NASDAQ: LFMD) stock, dramatically lowering its price objective to $8.00 from a previous $12.00. This downgrade reflects growing concerns over the telehealth company's financial performance, operational efficiency, and competitive landscape. The immediate